The renin-angiotensin-aldosterone system (RAAS) ranks among the most challenging puzzles in cardiovascular medicine [...].

3rd Department of Internal Medicine Faculty of Medicine Comenius University 83305 Bratislava Slovakia

Department of Cardiovascular Surgery Inselspital University Hospital of Bern Freiburgstrasse 18 3010 Bern Switzerland

Department of Physiology Faculty of Medicine Charles University 50003 Hradec Kralove Czech Republic

Institute of Experimental Endocrinology Biomedical Research Center Slovak Academy of Sciences 84505 Bratislava Slovakia

Institute of Normal and Pathological Physiology Centre for Experimental Medicine Slovak Academy of Sciences 84505 Bratislava Slovakia

Institute of Pathophysiology Faculty of Medicine Comenius University 81108 Bratislava Slovakia

Zobrazit více v PubMed

Simko F., Simko J. Heart failure and angiotensin converting enzyme inhibition: Problems and perspectives. Physiol. Res. 1999;48:1–8. PubMed

Unger T., Paulis L., Sica D.A. Therapeutic perspectives in hypertension: Novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches. Eur. Heart J. 2011;32:2739–2747. doi: 10.1093/eurheartj/ehr253. PubMed DOI PMC

Simko F., Pechanova O. Remodelling of the heart and vessels in experimental hypertension: Advances in protection. J. Hypertens. 2010;28(Suppl. 1):S1–S6. doi: 10.1097/01.hjh.0000388487.43460.db. PubMed DOI

Simko F., Baka T., Poglitsch M., Repova K., Aziriova S., Krajcirovicova K., Zorad S., Adamcova M., Paulis L. Effect of Ivabradine on a Hypertensive Heart and the Renin-Angiotensin-Aldosterone System in L-NAME-Induced Hypertension. Int. J. Mol. Sci. 2018;19:3017. doi: 10.3390/ijms19103017. PubMed DOI PMC

Paulis L., Rajkovicova R., Simko F. New developments in the pharmacological treatment of hypertension: Dead-end or a glimmer at the horizon? Curr. Hypertens. Rep. 2015;17:557. doi: 10.1007/s11906-015-0557-x. PubMed DOI PMC

Hrenak J., Simko F. Renin-Angiotensin System: An Important Player in the Pathogenesis of Acute Respiratory Distress Syndrome. Int. J. Mol. Sci. 2020;21:8038. doi: 10.3390/ijms21218038. PubMed DOI PMC

Rahman A., Sawano T., Sen A., Hossain A., Jahan N., Kobara H., Masaki T., Kosaka S., Kitada K., Nakano D., et al. Cardioprotective Effects of a Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, in Dahl Salt-Sensitive Hypertensive Rats. Int. J. Mol. Sci. 2021;22:2069. doi: 10.3390/ijms22042069. PubMed DOI PMC

Tigerstedt R., Bergman P.G. Niere und Kreislauf. Skand. Arch. Physiol. 1898;8:223–271. doi: 10.1111/j.1748-1716.1898.tb00272.x. DOI

Goldblatt H.J., Lynch J., Hanzal R.F., Summerville W.W. Studies on experimental hypertension. I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J. Exp. Med. 1934;59:347–380. doi: 10.1084/jem.59.3.347. PubMed DOI PMC

Braun-Menendez E., Fasciolo J.C., Leloir L.F., Muñoz J.M. The substance causing renal hypertension. J. Physiol. 1940;98:283–298. doi: 10.1113/jphysiol.1940.sp003850. PubMed DOI PMC

Mulrow P.J., Ganong W.R. Stimulation of aldosterone secretion by angiotensin II. Yale J. Biol. Med. 1961;33:386–395. PubMed PMC

Hall J.E., Guyton A.C., Jackson T.E., Coleman T.G., Lohmeier T.E., Trippodo N.C. Control of glomerular filtration rate by renin-angiotensin system. Am. J. Physiol. 1977;233:F366–F372. doi: 10.1152/ajprenal.1977.233.5.F366. PubMed DOI

Hall J.E. Historical perspective of the renin-angiotensin system. Mol. Biotechnol. 2003;24:27–39. doi: 10.1385/MB:24:1:27. PubMed DOI

Dzau V.J. Evolving concepts of the renin-angiotensin system. Focus on renal and vascular mechanisms. (4 Pt 2)Am. J. Hypertens. 1988;1:334S–337S. doi: 10.1093/ajh/1.4.334S. PubMed DOI

Bader M., Ganten D. Update on tissue renin–angiotensin systems. J. Mol. Med. 2008;86:615–621. doi: 10.1007/s00109-008-0336-0. PubMed DOI

Santos R.A., Brosnihan K.B., Chappell M.C., Pesquero J., Chernicky C.L., Greene L.J., Ferrario C.M. Converting enzyme activity and angiotensin metabolism in the dog brainstem. Hypertension. 1988;11:I153–I157. doi: 10.1161/01.HYP.11.2_Pt_2.I153. PubMed DOI

Santos R.A.S., Oudit G.Y., Verano-Braga T., Canta G., Steckelings U.M., Bader M. The renin-angiotensin system: Going beyond the classical paradigms. Am. J. Physiol. Heart Circ. Physiol. 2019;316:H958–H970. doi: 10.1152/ajpheart.00723.2018. PubMed DOI PMC

Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., Somasundaran M., Sullivan J.L., Luzuriaga K., Greenough T.C., et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–454. doi: 10.1038/nature02145. PubMed DOI PMC

Pfeffer M.A., Braunwald E., Moyé L.A., Basta L., Brown E.J., Jr., Cuddy T.E., Davis B.R., Geltman E.M., Goldman S., Flaker G.C., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med. 1992;327:669–677. doi: 10.1056/NEJM199209033271001. PubMed DOI

Simko F., Simko J., Fabryova M. ACE-inhibition and angiotensin II receptor blockers in chronic heart failure: Pathophysiological consideration of the unresolved battle. Cardiovasc. Drugs Ther. 2003;17:287–290. doi: 10.1023/A:1026215712983. PubMed DOI

Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J. The effect of spironolac-tone on morbidity and mortality in patients with severe heart failure.Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 1999;341:709–717. doi: 10.1056/NEJM199909023411001. PubMed DOI

Parving H.H., Brenner B.M., McMurray J.J., De Zeeuw D., Haffner S.M., Solomon S.D., Chaturvedi N., Ghadanfar M., Weissbach N., Xiang Z., et al. Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): Rationale and study design. Nephrol. Dial. Transplant. 2009;24:1663–1671. doi: 10.1093/ndt/gfn721. PubMed DOI

Yusuf S., Teo K.K., Pogue J., Dyal L., Copland I., Schumacher H., Dagenais G., Sleight P., Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 2008;358:1547–1559. doi: 10.1056/NEJMoa0801317. PubMed DOI

Mancia G., Fagard R., Narkiewicz K., Redon J., Zanchetti A., Böhm M., Christiaens T., Cifkova R., De Backer G., Dominiczak A., et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur. Heart J. 2013;34:2159–2219. doi: 10.1093/eurheartj/eht151. PubMed DOI

Esteras R., Perez-Gomez M.V., Rodriguez-Osorio L., Ortiz A., Fernandez-Fernandez B. Combination use of medicines from two classes of renin-angiotensin system blocking agents: Risk of hyperkalemia, hypotension, and impaired renal function. Ther. Adv. Drug. Saf. 2015;6:166–176. doi: 10.1177/2042098615589905. PubMed DOI PMC

Oudit G.Y., Pfeffer M.A. Plasma angiotensin-converting enzyme 2: Novel biomarker in heart failure with implications for COVID-19. Eur. Heart J. 2020;41:1818–1820. doi: 10.1093/eurheartj/ehaa414. PubMed DOI PMC

Vaduganathan M., Vardeny O., Michel T., McMurray J.J.V., Pfeffer M.A., Solomon S.D. Renin–angiotensin–aldosterone system inhibitors in patients with COVID-19. N. Engl. J. Med. 2020;382:1653–1659. doi: 10.1056/NEJMsr2005760. PubMed DOI PMC

Gheblawi M., Wang K., Viveiros A., Nguyen Q., Zhong J.C., Turner A.J., Raizada M.K., Grant M.B., Oudit G.Y. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res. 2020;126:1456–1474. doi: 10.1161/CIRCRESAHA.120.317015. PubMed DOI PMC

Liu Y., Yang Y., Zhang C., Huang F., Wang F., Yuan J., Wang Z., Li J., Feng C., Zhang Z., et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci. China Life Sci. 2020;63:364–374. doi: 10.1007/s11427-020-1643-8. PubMed DOI PMC

Fang L., Karakiulakis G., Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir. Med. 2020 doi: 10.1016/S2213-2600(20)30116-8. PubMed DOI PMC

Hrenak J., Zorad S., Simko F. Renin-angiotensin system and SARS-CoV-2 interaction: Underlying mechanisms and potential clinical implications. Gen. Physiol. Biophys. 2020;39:203–204. doi: 10.4149/gpb_2020019. PubMed DOI

Hrenak J., Paulis L., Simko F. N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP): Potential target molecule in research of heart, kidney and brain. Curr. Pharm. Des. 2015;21:5135–5143. doi: 10.2174/1381612821666150909093927. PubMed DOI

Koshy A.N., Murphy A.C., Farouque O., Ramchand J., Burrell L.M., Yudi M.B. Renin-angiotensin system inhibition and risk of infection and mortality in COVID-19: A systematic review and meta-analysis. Intern. Med. J. 2020;50:1468–1474. doi: 10.1111/imj.15002. PubMed DOI PMC

Hrenak J., Paulis L., Simko F. Angiotensin A/Alamandine/MrgD Axis: Another Clue to Understanding Cardiovascular Pathophysiology. Int. J. Mol. Sci. 2016;17:1098. doi: 10.3390/ijms17071098. PubMed DOI PMC

Steckelings U.M., Sumners C. Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists. Clin. Sci. (Lond.) 2020;134:2987–3006. doi: 10.1042/CS20200922. PubMed DOI

Sodhi C.P., Wohlford-Lenane C., Yamaguchi Y., Prindle T., Fulton W.B., Wang S., McCray P.B., Jr., Chappell M., Hackam D.J., Jia H., et al. Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg 9 bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration. Am. J. Physiol. Lung Cell. Mol. Physiol. 2018;314:L17–L31. doi: 10.1152/ajplung.00498.2016. PubMed DOI PMC

Mansour E., Bueno F.F., De Lima-Júnior J.C., Palma A., Monfort-Pires M., Bombassaro B., Araujo E.P., Bernardes A.F., Ulaf R.G., Nunes T.A., et al. Trials. Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: Study protocol for a three-armed randomized controlled trial. Int. J. Mol. Sci. 2021;22:71. doi: 10.1186/s13063-021-05027-9. PubMed DOI PMC

Esteban V., Ruperez M., Sánchez-López E., Rodríguez-Vita J., Lorenzo O., Demaegdt H., Vanderheyden P., Egido J., Ruiz-Ortega M. Angiotensin IV activates the nuclear transcription factor-kappaB and related proinflammatory genes in vascular smooth muscle cells. Circ. Res. 2005;96:965–973. doi: 10.1161/01.RES.0000166326.91395.74. PubMed DOI

D’Armiento J. Randomized Controlled Trial of Angiotensin 1-7 (TXA127) for the Treatment of Severe COVID-19. [(accessed on 19 March 2021)];2020 clinicaltrials.gov; Report No.: NCT04401423. Available online: https://clinicaltrials.gov/ct2/show/NCT04401423.

Lumpuy-Castillo J., Lorenzo-Almorós A., Pello-Lázaro A.M., Sánchez-Ferrer C., Egido J., Tuñón J., Peiró C., Lorenzo Ó. Cardiovascular Damage in COVID-19: Therapeutic Approaches Targeting the Renin-Angiotensin-Aldosterone System. Int. J. Mol. Sci. 2020;21:6471. doi: 10.3390/ijms21186471. PubMed DOI PMC

Bellis A., Mauro C., Barbato E., Trimarco B., Morisco C. The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19. Int. J. Mol. Sci. 2020;21:8612. doi: 10.3390/ijms21228612. PubMed DOI PMC

Wilcox C.S., Pitt B.J. Is spironolactone the preferred renin-angiotensin-aldosterone inhibitor for protection against COVID-19? Cardiovasc. Pharmacol. 2020 doi: 10.1097/FJC.0000000000000960. PubMed DOI

Simko F., Hrenak J., Dominguez-Rodriguez A., Reiter R.J. Melatonin as a putative protection against myocardial injury in COVID-19 infection. Editorial. Expert. Rev. Clin. Pharmacol. 2020;13:921–924. doi: 10.1080/17512433.2020.1814141. PubMed DOI

Sacubitril/Valsartan and Ivabradine Attenuate Left Ventricular Remodelling and Dysfunction in Spontaneously Hypertensive Rats: Different Interactions with the Renin-Angiotensin-Aldosterone System

The Impact of microRNAs in Renin-Angiotensin-System-Induced Cardiac Remodelling